Preferred Label : talazoparib;
MeSH note : inhibits both PARP1 and PARP2; structure in first source;
CISMeF synonym : BMN 673;
MeSH hyponym : BMN-673; BMN673;
MeSH CAS label : 3H-Pyrido(4,3,2-de)phthalazin-3-one, 5-fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-,
(8S,9R)-;
UNII : 9QHX048FRV;
Origin ID : C586365;
UMLS CUI : C4042960;
ATC code(s)
Currated CISMeF NLP mapping
MeSH indexing information
MeSH term(s) associated for indexing
Pharmacological action(s)
Record concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
https://www.has-sante.fr/jcms/p_3512093/fr/talzenna-talazoparib-cancer-de-la-prostate
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
Enzalutamide/Talazoparib Regimen
enzalutamide
metastatic castration resistant prostate cancer
adult
neoplasm metastasis
administration, oral
talazoparib
Poly(ADP-ribose) Polymerase Inhibitors
Product containing only talazoparib in oral dose form (medicinal product form)
evaluation of the transparency committee
talazoparib
prostatic neoplasms, Castration-Resistant
---
https://www.has-sante.fr/jcms/p_3433922/fr/talzenna-talazoparib-cancer-de-la-prostate
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
talazoparib
talazoparib
Poly(ADP-ribose) Polymerase Inhibitors
metastatic castration resistant prostate cancer
prostatic neoplasms, Castration-Resistant
neoplasm metastasis
evaluation of the transparency committee
---
https://ansm.sante.fr/actualites/avis-de-lansm-du-20-11-2023-sur-le-medicament-talzenna-dans-le-cadre-dune-demande-daap
2023
false
false
false
France
French
drug information
talazoparib
Talazoparib Tosylate
prostatic neoplasms, Castration-Resistant
metastatic castration resistant prostate cancer
talazoparib
---
https://ansm.sante.fr/tableau-acces-derogatoire/talazoparib-0-25-mg-gelule
2023
false
false
false
France
French
talazoparib
drug information
---
https://ansm.sante.fr/actualites/avis-de-lansm-du-13-04-2023-sur-le-medicament-talzenna-dans-le-cadre-dune-demande-daap
2023
false
false
false
France
French
drug information
administration, oral
talazoparib
talazoparib
Poly(ADP-ribose) Polymerase Inhibitors
adult
antineoplastic combined chemotherapy protocols
enzalutamide
prostatic neoplasms, Castration-Resistant
neoplasm metastasis
metastatic castration resistant prostate cancer
---
https://www.cancer.fr/catalogue-des-publications/inhibiteurs-de-parp-olaparib-niraparib-rucaparib-talazoparib
2022
false
false
false
France
practice guideline
talazoparib
olaparib
Poly(ADP-ribose) Polymerase Inhibitors
talazoparib
rucaparib
olaparib
niraparib
niraparib
olaparib
rucaparib
---
https://www.has-sante.fr/jcms/p_3245412/fr/talzenna
2021
false
false
false
France
administration, oral
talazoparib
talazoparib
Poly(ADP-ribose) Polymerase Inhibitors
breast neoplasms
evaluation of the transparency committee
phthalazines
---
https://www.ema.europa.eu/en/medicines/human/EPAR/talzenna
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
talazoparib
talazoparib
breast neoplasms
talazoparib
Poly(ADP-ribose) Polymerase Inhibitors
Poly(ADP-ribose) Polymerase Inhibitors
administration, oral
product surveillance, postmarketing
adult
genes, BRCA1
genes, BRCA2
mutation
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
phthalazines
phthalazines
---
https://www.has-sante.fr/jcms/p_3135577/fr/talzenna
2019
false
false
false
France
French
administration, oral
insurance, health, reimbursement
treatment outcome
talazoparib
talazoparib
breast neoplasms
breast neoplasms
genes, BRCA1
genes, BRCA2
mutation
Poly(ADP-ribose) Polymerase Inhibitors
evaluation of the transparency committee
phthalazines
---